The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic Anemia

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
A single-arm study utilizing a 6 x 4 expansion design using daratumumab SC treatment for patients with refractory Autoimmune Hemolytic Anemia.
Epistemonikos ID: b342256f9cb8dba974394893b203a13302559022
First added on: May 09, 2024